We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

6 hedge funds and large institutions have $129K invested in Indaptus Therapeutics in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

50% more funds holding

Funds holding: 4 → 6 (+2)

37% more capital invested

Capital invested by funds: $93.7K → $129K (+$34.9K)

1.31% more ownership

Funds ownership: 1.84% → 3.15% (+1.3%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$83.7K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$57.9K
3
Morgan Stanley
Morgan Stanley
New York
+$5.78K
4
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC)
Nebraska
+$4

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$84.4K
2
TRCT
Tower Research Capital (TRC)
New York
-$2.7K
3
Bank of America
Bank of America
North Carolina
-$73

INDP Hedge Fund Activity: Q1 2026 in Review

6 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2026, worth a combined $129K — up 37% from $93.7K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new INDP positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $83.7K. The largest seller was UBS Group, exiting entirely with an estimated $84.4K sold.

  • 6 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2026, up from 4 in Q4 2025.
  • Funds reported $129K of Indaptus Therapeutics stock for Q1 2026, up 37% quarter-over-quarter.
  • 4 funds opened new Indaptus Therapeutics positions in Q1 2026 and 2 closed out, a net change of +2 holders.
  • The largest Indaptus Therapeutics buyer in Q1 2026 was Citadel Advisors, an estimated $83.7K added.
  • The largest Indaptus Therapeutics seller in Q1 2026 was UBS Group, an estimated $84.4K sold.

Based on aggregated 13F filings for Q1 2026.